Everything below concerns REV-ERB agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-05-19. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
==== The storage iron pool ==== Iron can be stored in ferritin as ferric iron due to the ferroxidase activity of the ferritin heavy chain. Dysfunctional ferritin may accumulate as hemosiderin, which can be problematic in cases of iron overload. The ferritin storage iron pool is much larger than the labile iron pool, ranging in concentration from 0.7 mM to 3.6 mM.
Just Stop Oil protesters vandalise Stonehenge by spraying the megaliths with orange cornflour powder paint. A police officer working as part of the prime minister's close protection team is suspended and later arrested as part of an ongoing investigation into bets on the date of the general election. BBC News reports that Laura Saunders, the Conservative candidate for Bristol North West, has become the second Conservative candidate to face an investigation by the Gambling Commission over betting on the date of the general election. It is subsequently reported that her husband, Tony Lee, the Conservative Party's campaigns director, is also being investigated by the commission. 20 June The Bank of England holds interest rates at 5.25%, its seventh consecutive freeze. Sunak says he is "incredibly angry" to learn of allegations that members of his party have betted on the date of the election, and that he will "boot out" anyone found to have broken the law. The number of people becoming ill from a recent outbreak of E. coli across the UK reaches 256, which includes 86 hospitalisations. The UK Health Security Agency reports that case numbers have now slowed, and that everything possible is being done to find the root cause, which may be pre-packaged sandwiches containing lettuce. 21 June Nigel Farage tells the BBC that he believes the Russo-Ukrainian War to have been precipitated by the West's eastward expansion of NATO and the European Union, but that the war itself is Vladimir Putin's fault.
D-amino acid + H2O + acceptor ⇌ a 2-oxo acid + NH3 + reduced acceptor This reaction is distinct from the oxidation reaction catalysed by D-amino acid oxidase that uses oxygen as a second substrate, as the dehydrogenase can use many different compounds as electron acceptors, with the physiological substrate being coenzyme Q. D-amino acid dehydrogenase is an enzyme that catalyzes NADPH from NADP+ and D-glucose to produce D-amino acids and glucose dehydrogenase. Some but not limited to these amino acids are D-leucine, D-isoleucine, and D-valine, which are essential amino acids that humans cannot synthesize because they are not included in their diet. Moreover, D-amino acids catalyzes the formation of 2-oxo acids to produce D-amino acids in the presence of DCIP which is an electron acceptor. D-amino acids are used as components of pharmaceutical products, such as antibiotics, anticoagulants, and pesticides, because they have been shown to be not only more potent than their L enantiomers, but also more resistant to enzyme degradation. D-amino acid dehydrogenase enzymes have been synthesized via mutagenesis with an ability to produce straight, branched, cyclic aliphatic and aromatic D-amino acids. Solubilized D-amino acid dehydrogenase tends to increase its affinity for D-alanine, D-asparagine, and D-α-amino-n-butyrate. In E. coli K12 D-amino acid dehydrogenase is most active with D-alanine as its substrate, as this amino acid is the sole source of carbon, nitrogen, and energy. The enzyme works optimally at pH 8.9 and has a Michaelis constant for D-alanine equal to 30 mM.
Francis Harry Compton Crick (8 June 1916 – 28 July 2004) was an English molecular biologist, biophysicist, and neuroscientist. He, James Watson, Rosalind Franklin, and Maurice Wilkins played crucial roles in deciphering the helical structure of the DNA molecule. Crick and Watson's paper in Nature in 1953 laid the groundwork for understanding DNA structure and functions. Together with Maurice Wilkins, they were jointly awarded the 1962 Nobel Prize in Physiology or Medicine "for their discoveries concerning the molecular structure of nucleic acids and its significance for information transfer in living material". Crick was an important theoretical molecular biologist and played a crucial role in research related to revealing the helical structure of DNA. He is widely known for the use of the term "central dogma" to summarise the idea that once information is transferred from nucleic acids (DNA or RNA) to proteins, it cannot flow back to nucleic acids. In other words, the final step in the flow of information from nucleic acids to proteins is irreversible. During the remainder of his career, Crick held the post of J.W. Kieckhefer Distinguished Research Professor at the Salk Institute for Biological Studies in La Jolla, California. His later research centred on theoretical neurobiology and attempts to advance the scientific study of human consciousness. Crick remained in this post until his death in 2004; "he was editing a manuscript on his death bed, a scientist until the bitter end" according to Christof Koch.
=== Approval history === On 22 December 2009, a New Drug Application (NDA) was submitted to the Food and Drug Administration (FDA) in the United States. On 16 September 2010, an FDA advisory panel voted 9–5 against approval of the drug based on concerns over both efficacy and safety, particularly the findings of mammary gland tumors of female rats. On 23 October 2010, the FDA decided not to approve the drug based on the available data. This was not only because cancer promoting properties could not be ruled out, but also because the weight loss efficacy was considered "marginal". On 10 May 2012, after a new round of studies submitted by Arena, an FDA panel voted to recommend lorcaserin with certain restrictions and patient monitoring. The restrictions include patients with a BMI of over 30, or with a BMI over 27 and a comorbidity such as high blood pressure or type 2 diabetes. On 27 June 2012, the FDA approved lorcaserin for use in adults with a body mass index (BMI) of 30 or greater (obese), or adults with a BMI of 27 or greater (overweight) and who had at least one weight-related condition such as high blood pressure (hypertension), type 2 diabetes, or high cholesterol (dyslipidemia). On 15 July 2016, the FDA approved the extended release version of lorcaserin for weight management with once-daily dosing instead of twice daily dosing. On 17 September 2020, the FDA withdrew approval for lorcaserin and for extended-release lorcaserin tablets.
Sources: en.wikipedia.org
== Experimental chemistry == Meitnerium is the first element on whose chemistry has not yet been investigated. Unambiguous determination of its chemical properties is yet to have been established due to the short half-lives of meitnerium isotopes and a limited number of likely volatile compounds that could be studied on a tiny scale. One of the few meitnerium compounds that are likely to be volatile enough is meitnerium hexafluoride MtF6, as its lighter homolog iridium hexafluoride (IrF6) is volatile above 60°C, so the analogous compound of meitnerium might also be volatile enough; a volatile octafluoride MtF8 might also be possible. For chemical studies on a transactinide, at least four atoms must be produced, the half-life of the isotope used must be ≥1 second, and the rate of production must be at least one atom per week. Even though the half-life of 278Mt, the most stable confirmed isotope, is 4.5 seconds, long enough for chemical studies, another obstacle is the need to increase the rate of production of meitnerium and allow experiments to carry on for weeks or months so that statistically significant results can be obtained. Separation and detection must be carried out continuously to separate out the meitnerium isotopes and have automated systems experiment on the gas-phase and solution chemistry of meitnerium, as the yields for heavier elements are predicted to be smaller than those for lighter elements; some of the separation techniques used for bohrium and hassium could be reused.
Dylan Thomas was born on 27 October 1914 in Swansea, the son of Florence Hannah (née Williams; 1882–1958), a seamstress, and David John 'Jack' Thomas (1876–1952), a teacher. His father had a first-class honours degree in English from University College, Aberystwyth, and ambitions to rise above his position teaching English literature at the local grammar school. Thomas had one sibling, Nancy Marles (1906–1953), who was eight years his senior. The red-brick, semi-detached house at 5 Cwmdonkin Drive (in the Uplands area), in which Thomas was born and lived until he was 23, had been bought by his parents a few months before his birth. At the 1921 census, Nancy and Dylan are noted as speaking both Welsh and English. Their parents were also bilingual in English and Welsh, and Jack Thomas taught Welsh at evening classes. One of their Swansea relations has recalled that, at home, "Both Auntie Florrie and Uncle Jack always spoke Welsh." There are three accounts from the 1940s of Dylan singing Welsh hymns and songs, and of speaking a little Welsh. Thomas's father chose the name Dylan, which could be translated as "son of the sea" after Dylan ail Don, a character in The Mabinogion. His middle name, Marlais, was given in honour of his great-uncle, William Thomas, a Unitarian minister and poet whose bardic name was Gwilym Marles. The name Dylan being pronounced [ˈdəlan] in Welsh caused his mother to worry that he might be teased as the "dull one". When he broadcast on Welsh BBC early in his career, he was introduced using this pronunciation.
The latter had expelled the Umayyads from the Hejaz and among the exiles to Syria was Marwan ibn al-Hakam, an Umayyad elder. Ubayd Allah persuaded Marwan, who was preparing to recognize Ibn al-Zubayr's sovereignty, to enter his candidacy as Mu'awiya II's successor. The Umayyads' principal Syrian allies, the Banu Kalb, had sought to maintain Umayyad rule and nominated Mu'awiya II's half-brother Khalid as caliph. However, the other pro-Umayyad Syrian tribes viewed Khalid as too young and inexperienced, and rallied around Marwan, who was ultimately chosen as caliph.
== History == The nitrophenyl ethers are a well-known class of herbicides, the oldest member of which was nitrofen, invented by Rohm & Haas and first registered for sale in 1964. This area of chemistry became very competitive, with the Mobil Oil Corporation's filing in 1969 and grant in 1974 of a patent to the structural analog with a COOCH3 group adjacent to the nitro group of nitrofen. This product, bifenox, was launched with the brand name Mowdown in 1981. Meanwhile, Rohm & Haas introduced acifluorfen (as its sodium salt with brand name Blazer) in 1980, having developed it under the code number RH-6201. It had much improved properties including a wider spectrum of herbicidal effect and good safety to soybean crops. The first patent for the material was published in December 1975, although an earlier Belgian patent published in September 1973 had described related chemistry.
On June 11, 2026, and in preparation for the 2026 FIFA World Cup, NASA conducted experiments aboard the International Space Station using soccer balls to study how mass distribution and embedded sensor technology affect ball motion and stability in microgravity. According to NASA, the research contributed to the development and evaluation of technologies used in the 2026 FIFA World Cup official match ball. The Trionda Final was announced by Adidas on July 6, 2026, as the official match ball to be used for the semifinals, match for third place, and final. It features a gold, black, and red color scheme, with the host cities' names printed on it.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.